RADIANT Trials: Everolimus Outshines Placebo in Neuroendocrine Tumors
Major Finding: Everolimus plus octreotide LAR was associated with a median progression-free survival of 16.4 months vs. 11.3 months for octreotide LAR plus placebo in patients with advanced, nonpancreatic neuroendocrine tumors (HR, 0.77; P = .026). In patients with advanced pancreatic NET, everolimus increased median progression-free survival 2.4-fold.
Data Source: Two randomized, phase III clinical trials: RADIANT-2 in 429 patients with advanced nonpancreatic NET, and RADIANT-3 in 410 patients with advanced pancreatic NET.
Disclosures: Novartis sponsored both studies. Dr. Pavel, Dr Yao, and several coauthors have received honoraria, consultancy fees, and research support from Novartis, or were employees or stockholders in the company. Dr. Yao has also received research support from Genentech and acted as an advisor to the Ipsen Group, Pfizer, and Endo Pharmaceuticals. Dr. Ducreux had no personal disclosures other than noting some of his patients had been treated in RADIANT-2 and -3.
“A lot of treatments are more active in pancreatic NET than in nonpancreatic NET,” he added with the observation that pancreatic NET is more aggressive, but easier to treat.
In a press statement, Dr. Roberto Labianca from the Ospedali Riuniti di Bergamo (Italy) said of the RADIANT-2 results, “This trial should be considered a practice-changing achievement, but it is essential that selection criteria are refined in order to identify the population more likely to respond to this approach.”
Novartis sponsored both studies. Dr. Pavel and Dr. Yao and several coauthors have received honoraria, consultancy fees, and research support from Novartis, or were employees or stockholders in the company. Dr. Yao has also received research support from Genentech Inc. and acted as an advisor to the Ipsen Group, Pfizer Inc., and Endo Pharmaceuticals. Dr. Ducreux had no personal disclosures other than noting some of his patients had been treated in RADIANT-2 and -3.
